Search company, investor...
Search
Biodesix company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biodesix.com

Founded Year

2005

Stage

IPO | IPO

Total Raised

$259.21M

Date of IPO

10/28/2020

Market Cap

0.05B

Stock Price

1.28

About Biodesix

Biodesix (NASDAQ: BDSX) is a fully integrated molecular diagnostics company advancing the development of products for personalized medicine. Biodesix develops, validates, and commercializes VeriStrat, a serum proteomic test currently available to help physicians guide therapy for patients with advanced non-small-cell lung cancer.

Biodesix Headquarters Location

2970 Wilderness Place Suite 100

Boulder, Colorado, 80301,

United States

303-417-0500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Biodesix

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biodesix in 2 CB Insights research briefs, most recently on Mar 12, 2020.

Expert Collections containing Biodesix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biodesix is included in 6 Expert Collections, including Cancer.

C

Cancer

3,710 items

Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'

M

Medical Devices

8,487 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

O

Omics

1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

H

Health IT

7,901 items

P

Precision Medicine Tech Market Map

160 items

This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.

Biodesix Patents

Biodesix has filed 55 patents.

The 3 most popular patent topics include:

  • Classification algorithms
  • Clusters of differentiation
  • Molecular biology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/18/2017

12/7/2021

Molecular biology, Rare diseases, Inflammations, Transcription factors, Syndromes

Grant

Application Date

8/18/2017

Grant Date

12/7/2021

Title

Related Topics

Molecular biology, Rare diseases, Inflammations, Transcription factors, Syndromes

Status

Grant

Latest Biodesix News

Biodesix to Participate in Two Upcoming Investor Conferences in September

Sep 6, 2022

09/06/2022 | 06:01am EDT Message : *Required fields Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 20th Annual Global Healthcare Conference Date: Tuesday, September 13, 2022 at 9:10 a.m. ET Format: Fireside Chat and 1x1 meetings Location: Sheraton Hotel, New York, NY Details: The fireside chat will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at www.biodesix.com . H.C. Wainwright 24th Annual Global Investment Conference Dates: September 12-14, 2022 About Biodesix Biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. The blood based Nodify Lung® nodule risk assessment testing strategy, consisting of the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. The blood based IQLung™ strategy for lung cancer patients integrates the GeneStrat® ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. Biodesix also leverages the proprietary and advanced Diagnostic Cortex® AI (Artificial Intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. Biodesix launched the SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™ Neutralization Test Kit, GenScript, Inc,) in response to the global pandemic and virus that impacts the lung and causes COVID-19. For more information about Biodesix, visit biodesix.com . Note Regarding Forward-Looking Statements This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions. Forward-looking statements may include information concerning the impact of the COVID-19 pandemic on Biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. The Company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of Biodesix’s most recent annual report on Form 10-K, filed March 14, 2022 or subsequent quarterly reports on Form 10-Q during 2022, if applicable. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005149/en/ © Business Wire 2022

Biodesix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biodesix Rank

  • When was Biodesix founded?

    Biodesix was founded in 2005.

  • Where is Biodesix's headquarters?

    Biodesix's headquarters is located at 2970 Wilderness Place, Boulder.

  • What is Biodesix's latest funding round?

    Biodesix's latest funding round is IPO.

  • How much did Biodesix raise?

    Biodesix raised a total of $259.21M.

  • Who are the investors of Biodesix?

    Investors of Biodesix include Paycheck Protection Program, Crabtree Ventures, Meakem Becker Venture Capital, Birchview Capital, Innovatus Capital Partners and 8 more.

  • Who are Biodesix's competitors?

    Competitors of Biodesix include Dilon Technologies, Upromise, Akonni Biosystems, Exagen, Signature Diagnostics and 11 more.

You May Also Like

P
ProteoGenix

ProteoGenix offers maternal-fetal diagnostics

H
Hx Diagnostics

Hx Diagnostics offers rapid diagnostics for seasonal and emerging infectious diseases.

L
Labnow

LabNow has developed the LabNow System to conduct healthcare-related diagnostics at the point-of-care.

A
AngioLogix

AngioLogix is a provider of cardiovascular health diagnostics.

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

C
CyberGene

CyberGene manufactures custom oligos, ChromoQuant QF-PCR kit for In Vitro Diagnostics and performes DNA sequencing

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.